Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II

To overcome poor pharmacokinetics and toxicity of triptolide (TPL), a natural compound that exhibits potent anticancer activities, we developed a novel antibody-drug conjugate (ADC) to specifically deliver TPL to epidermal growth factor receptor (EGFR)-overexpressing non-small cell lung cancer (NSCL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther Oncolytics
Autors principals: Zhang, Keqiang, Ma, Yuelong, Guo, Yuming, Sun, Ting, Wu, Jun, Pangeni, Rajendra P., Lin, Min, Li, Wendong, Horne, David, Raz, Dan J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Gene & Cell Therapy 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7394741/
https://ncbi.nlm.nih.gov/pubmed/32775615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2020.07.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars